NCT04873362 2026-03-04
Astefania
Hoffmann-La Roche
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT07421141 2026-02-27
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Active not recruiting
NCT03587740 2026-02-17
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT06663787 2025-11-28
HER2 CR
Nagoya City University
Active not recruiting
NCT04733118 2025-11-20
PHERGAIN-2
MedSIR
Phase 2 Active not recruiting
NCT03529110 2025-10-21
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT02326974 2025-03-05
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02568839 2020-08-13
PREDIX HER2
Karolinska University Hospital
Phase 2/3 Active not recruiting